J B Chemicals & Pharmaceuticals Ltd

J B Chemicals & Pharmaceuticals Ltd

₹ 1,646 -0.64%
23 Feb - close price
About

J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]

Key Points

Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]

  • Market Cap 25,542 Cr.
  • Current Price 1,646
  • High / Low 1,940 / 875
  • Stock P/E 49.7
  • Book Value 175
  • Dividend Yield 0.54 %
  • ROCE 22.4 %
  • ROE 17.6 %
  • Face Value 1.00

Pros

  • Company has been maintaining a healthy dividend payout of 31.7%

Cons

  • Stock is trading at 9.40 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
548 528 606 593 601 625 785 809 793 762 896 882 845
377 405 442 466 473 500 612 625 618 599 664 638 621
Operating Profit 171 124 164 127 128 125 173 185 175 164 232 244 223
OPM % 31% 23% 27% 21% 21% 20% 22% 23% 22% 21% 26% 28% 26%
56 25 13 20 5 2 1 1 3 5 6 8 7
Interest 1 1 1 1 1 2 6 8 8 14 12 10 12
Depreciation 17 17 18 16 17 22 26 28 28 32 31 32 34
Profit before tax 208 132 158 129 114 103 142 150 141 122 194 209 184
Tax % 26% 24% 25% 24% 26% 18% 26% 26% 25% 28% 27% 28% 27%
154 101 119 98 84 85 105 111 106 88 142 151 134
EPS in Rs 9.97 6.51 7.69 6.32 5.43 5.49 6.79 7.18 6.86 5.66 9.19 9.72 8.61
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
802 866 1,022 1,144 1,210 1,344 1,408 1,643 1,775 2,043 2,424 3,149 3,385
701 760 874 964 1,004 1,112 1,191 1,337 1,397 1,482 1,881 2,454 2,522
Operating Profit 101 106 148 180 206 232 218 306 378 560 543 696 862
OPM % 13% 12% 14% 16% 17% 17% 15% 19% 21% 27% 22% 22% 25%
789 27 -27 11 58 50 37 41 41 112 39 10 25
Interest 24 4 6 7 11 5 3 5 3 7 5 36 49
Depreciation 22 25 28 39 41 47 57 56 66 69 73 114 129
Profit before tax 843 104 87 146 212 230 194 287 349 597 505 555 709
Tax % 20% 23% 30% 31% 23% 20% 28% 32% 22% 25% 24% 26%
678 79 62 100 163 184 139 194 272 449 386 410 514
EPS in Rs 40.02 4.69 3.63 5.92 9.58 10.85 8.28 12.05 17.60 28.98 24.93 26.48 33.18
Dividend Payout % 51% 32% 41% 118% 26% 5% 12% 21% 31% 28% 33% 34%
Compounded Sales Growth
10 Years: 14%
5 Years: 17%
3 Years: 21%
TTM: 12%
Compounded Profit Growth
10 Years: 21%
5 Years: 31%
3 Years: 16%
TTM: 26%
Stock Price CAGR
10 Years: 38%
5 Years: 58%
3 Years: 43%
1 Year: 67%
Return on Equity
10 Years: 15%
5 Years: 18%
3 Years: 20%
Last Year: 18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 17 17 17 17 17 17 17 16 15 15 15 15 16
Reserves 953 1,003 1,026 978 1,167 1,347 1,425 1,464 1,420 1,794 2,119 2,465 2,701
71 50 93 127 193 49 29 26 29 45 55 572 437
157 230 215 365 270 262 294 286 349 376 412 495 645
Total Liabilities 1,198 1,300 1,351 1,487 1,648 1,674 1,765 1,792 1,814 2,231 2,601 3,547 3,799
276 334 311 329 440 679 640 621 651 634 1,277 1,901 1,917
CWIP 39 5 46 55 135 4 17 15 16 26 19 55 72
Investments 302 398 500 552 479 411 434 457 403 678 13 206 315
581 563 494 552 594 580 674 699 743 894 1,293 1,385 1,495
Total Assets 1,198 1,300 1,351 1,487 1,648 1,674 1,765 1,792 1,814 2,231 2,601 3,547 3,799

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
880 84 -14 127 140 201 123 194 276 315 170 626
-261 -116 -142 -112 -26 -45 -21 -28 24 -231 2 -962
-526 -31 12 -1 -100 -184 -60 -156 -306 -87 -138 357
Net Cash Flow 93 -63 -144 13 15 -28 43 11 -6 -3 34 20

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 62 81 84 84 82 72 78 68 71 70 84 67
Inventory Days 117 104 120 122 146 138 145 149 159 181 178 134
Days Payable 51 60 54 63 71 68 75 72 97 97 97 75
Cash Conversion Cycle 128 124 150 143 158 142 148 146 133 153 164 127
Working Capital Days 98 80 99 56 96 88 101 97 87 99 127 102
ROCE % 11% 8% 13% 13% 15% 14% 11% 18% 23% 33% 23% 22%

Shareholding Pattern

Numbers in percentages

33 Recently
Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
55.91% 55.91% 55.91% 54.00% 54.00% 54.00% 53.96% 53.95% 53.93% 53.91% 53.86% 53.83%
7.54% 8.37% 8.74% 9.12% 9.22% 8.85% 8.66% 8.81% 8.62% 9.53% 10.05% 10.35%
13.17% 13.13% 15.23% 16.26% 16.89% 17.80% 18.47% 18.55% 19.08% 18.65% 18.58% 18.53%
23.38% 22.58% 20.12% 20.62% 19.89% 19.35% 18.91% 18.72% 18.35% 17.90% 17.50% 17.27%
No. of Shareholders 65,71870,74071,78864,86161,31460,26858,62959,77956,63355,96560,81763,230

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls